Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles
Current Oncology · 29.11.2023 · 30 (12) · 10211-10223
DOI: 10.3390/curroncol30120743 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 29.11.2023. Verfasst von Mary Anne Fenton und 2 weiteren Autor:innen. Beteiligte Einrichtung: Legorreta Cancer Center, Brown University, Providence, RI 02903, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody drug conjugates (ADCs) have emerged as a highly effective treatment strategy across breast cancer (BC) subtypes, including human epidermal growth factor receptor 2-positive (HER2+), hormone-receptor positive (ER/PR+), and triple-negative breast cancer (TNBC). Over the past twenty years, ADCs have undergone relevant evolutions, from target diversity to payload ratio, to linker design, allowing for a progressive increase in their efficacy. From the first-generation ADC, trastuzumab emtansine (T-DM1), approved in 2013 for HER2+ breast cancer, to next generation ADCs such as sacituzumab govitecan and trastuzumab deruxtecan, to emerging ADCs on the horizon, we continue to see unparalleled efficacy compared to traditional chemotherapy. However, each ADC has brought a new cadre of adverse events for clinicians and patients to manage. Importantly, with the development and approval of several ADCs to treat metastatic breast cancer, there are unanswered clinical questions surrounding how to optimally sequence treatment for patients who may be candidates for more than one ADC and, in general, how to treat patients beyond progression on ADCs. From bench to bedside, in this review, we will discuss the pharmacology and current indications for the novel ADCs trastuzumab deruxtecan and sacituzumab govitecan. Highlighting emerging ADCs and ongoing clinical trials, we will anticipate the changes in the breast cancer treatment paradigm. Lastly, we will outline the available data and current approaches for adverse event management and sequencing strategies for ADCs in clinical practice, including proposed mechanisms of resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Legorreta Cancer Center, Brown University, Providence, RI 02903, USA.
- Lifespan Cancer Institute, Providence, RI 02903, USA.
- Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.
- Breast Oncology Program, Dana Farber Brigham Cancer Center, Boston, MA 02215, USA.
- Harvard Medical School, Boston, MA 02215, USA.
- Department of Oncology and Onco-Hematology, University of Milan, 20122 Milan, Italy.
ORCID-Profile: Paolo Tarantino, Stephanie L Graff
Zitieren
APA
Fenton, M. A., Tarantino, P., & Graff, S. L. (2023). Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Current Oncology, 30(12), 10211-10223. https://doi.org/10.3390/curroncol30120743
Vancouver
Fenton MA, Tarantino P, Graff SL. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Current Oncology. 2023;30(12):10211-10223. doi:10.3390/curroncol30120743
BibTeX
@article{Fenton2023,
author = {Fenton, Mary Anne and Tarantino, Paolo and Graff, Stephanie L},
title = {Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {12},
pages = {10211--10223},
doi = {10.3390/curroncol30120743}
}
EUVIMED